{"DataElement":{"publicId":"58208","version":"3","preferredName":"CLL Leukemia RAI Stage","preferredDefinition":"stage of chronic lymphocytic leukemia according to the Rai stage classification.","longName":"CLL_LEUK_RAI_ST","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2189808","version":"1","preferredName":"CLL Leukemia Rai Description","preferredDefinition":"information related to the Rai stage or description for chronic lymphocytic leukemia.","longName":"CLL_LEUK_RAI_DESC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206660","version":"1","preferredName":"CLL Leukemia","preferredDefinition":"The most common type of chronic lymphoid leukemia, and comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  The clinical course is indolent, but this type of leukemia is not considered to be curable with available therapy. (WHO, 2001) -- 2003:A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","longName":"C3163:C3161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FEFE-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660713","version":"1","preferredName":"Rai Staging System Description ","preferredDefinition":"A staging system for Chronic Lymphocytic Leukemia.  Stage 0: absolute lymphocytosis (>15,000 per cubic millimeter) without adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia; Stage I: absolute lymphocytosis with lymphadenopathy without hepatosple:Description; a statement that represents something in words.","longName":"C20115:C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rai Staging System","conceptCode":"C20115","definition":"A staging system for Chronic Lymphocytic Leukemia.  Stage 0: absolute lymphocytosis (>15,000 per cubic millimeter) without adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia; Stage I: absolute lymphocytosis with lymphadenopathy without hepatosplenomegaly, anemia, or thrombocytopenia; Stage II: absolute lymphocytosis with either hepatomegaly or splenomegaly, with or without lymphadenopathy; Stage III: absolute lymphocytosis and anemia (hemoglobin <11 g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly; Stage IV: absolute lymphocytosis and thrombocytopenia (<100,000 per cubic millimeter) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anemia.  (from OncoLink)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-CB3A-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6406F92-0805-4359-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018505","version":"1","preferredName":"CLL Leukemia RAI Stage","preferredDefinition":"the RAI stage for a CLL (chronic lymphoblastic leukemia) leukemia.","longName":"CLL_LEUK_RAI_ST","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"9","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage 0","valueDescription":" Lymphocytosis in blood with lymphocyte count > 15,000/mcl and bone marrow populated with mature lymphocytes comprising >40% of nucleated cells","ValueMeaning":{"publicId":"2571752","version":"1","preferredName":" Lymphocytosis in blood with lymphocyte count > 15,000/mcl and bone marrow populated with mature lymphocytes comprising >40% of nucleated cells","longName":"2571752","preferredDefinition":"Lymphocytosis in blood with lymphocyte count > 15,000/mcl and bone marrow populated with mature lymphocytes comprising >40% of nucleated cells","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E555-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"REEVESD","dateModified":"2007-09-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A32D94-FB1F-0C02-E034-0003BA12F5E7","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Stage I","valueDescription":"SAME AS STAGE 0 WITH LYMPHADENOPATHY","ValueMeaning":{"publicId":"2559996","version":"1","preferredName":"SAME AS STAGE 0 WITH LYMPHADENOPATHY","longName":"2559996","preferredDefinition":"SAME AS STAGE 0 WITH LYMPHADENOPATHY","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B769-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A32D94-FB23-0C02-E034-0003BA12F5E7","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Stage II","valueDescription":"INCLUDES SAME DEGREE OF LYMPHOCYTOSIS AS STAGE 0, PLUS ENLARGED SPLEEN AND/OR LIVER","ValueMeaning":{"publicId":"2558955","version":"1","preferredName":"INCLUDES SAME DEGREE OF LYMPHOCYTOSIS AS STAGE 0, PLUS ENLARGED SPLEEN AND/OR LIVER","longName":"2558955","preferredDefinition":"INCLUDES SAME DEGREE OF LYMPHOCYTOSIS AS STAGE 0, PLUS ENLARGED SPLEEN AND/OR LIVER","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B358-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A32D94-FB27-0C02-E034-0003BA12F5E7","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Stage III","valueDescription":" Includes lymphocytosis and anemia defined as Hgb <11 g/dl or Hct <33%. Physical findings of lymphadenopathy, hepatomegaly or splenomegaly are not required. No distinction with regard to type of anemia (i.e. hemolytic) is made","ValueMeaning":{"publicId":"2571753","version":"1","preferredName":" Includes lymphocytosis and anemia defined as Hgb <11 g/dl or Hct <33%. Physical findings of lymphadenopathy, hepatomegaly or splenomegaly are not required. No distinction with regard to type of anemia (i.e. hemolytic) is made","longName":"2571753","preferredDefinition":"Includes lymphocytosis and anemia defined as Hgb <11 g/dl or Hct <33%. Physical findings of lymphadenopathy, hepatomegaly or splenomegaly are not required. No distinction with regard to type of anemia (i.e. hemolytic) is made","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E556-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"REEVESD","dateModified":"2007-09-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A32D94-FB2B-0C02-E034-0003BA12F5E7","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Stage IV","valueDescription":"Includes the findings at diagnosis of lymphocytosis as defined in Stage 0, with thrombocytopenia <100,000/mcl. Anemia and organomegaly may be absent.","ValueMeaning":{"publicId":"2571754","version":"1","preferredName":"Includes the findings at diagnosis of lymphocytosis as defined in Stage 0, with thrombocytopenia <100,000/mcl. Anemia and organomegaly may be absent.","longName":"2571754","preferredDefinition":"Includes the findings at diagnosis of lymphocytosis as defined in Stage 0, with thrombocytopenia <100,000/mcl. Anemia and organomegaly may be absent.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E557-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"CAMPBELB","dateModified":"2004-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2A32D94-FB2F-0C02-E034-0003BA12F5E7","beginDate":"2004-08-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Intermediate","valueDescription":"Intermediate Rai Stage","ValueMeaning":{"publicId":"6454296","version":"1","preferredName":"Intermediate Rai Stage","longName":"6454296","preferredDefinition":"Lying between two extremes in time or space or degree.: A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intermediate","conceptCode":"C73705","definition":"Lying between two extremes in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rai Stage","conceptCode":"C141207","definition":"A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"773FE5BF-81BB-1453-E053-F662850AE5E9","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-02","modifiedBy":"ONEDATA","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"773FE5BF-81D4-1453-E053-F662850AE5E9","beginDate":"2018-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-02","modifiedBy":"ONEDATA","dateModified":"2018-10-02","deletedIndicator":"No"},{"value":"High","valueDescription":"High Rai Stage","ValueMeaning":{"publicId":"6454297","version":"1","preferredName":"High Rai Stage","longName":"6454297","preferredDefinition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.: A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rai Stage","conceptCode":"C141207","definition":"A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"773FE5BF-81E4-1453-E053-F662850AE5E9","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-02","modifiedBy":"ONEDATA","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"773FE5BF-81FD-1453-E053-F662850AE5E9","beginDate":"2018-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-02","modifiedBy":"ONEDATA","dateModified":"2018-10-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2428501","version":"1","preferredName":"Stage","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"053C2A34-089B-693F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-11","modifiedBy":"ONEDATA","dateModified":"2005-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B10CD6-29B1-48A1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-20","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-20","modifiedBy":"MORENOC","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811795","version":"1","longName":"CLL Prev Untreated","context":"CTEP"},{"publicId":"2811924","version":"1","longName":"CLL Relapse/Refract","context":"CTEP"}]},{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000201","version":"1","longName":"Leukemia","context":"NCIP"},{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461152","version":"1","longName":"Hematologic Staging","context":"NCIP"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000689","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCI Standards"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"CLLP_DADX_rai_stage","type":"NMDP_FN","context":"NHLBI"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"CLL_LEUK_RAI_ST","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Rai CLL Stage","url":null,"context":"CTEP"},{"name":"Rai Stage Classification","type":"Preferred Question Text","description":"Rai Stage Classification","url":null,"context":"CTEP"},{"name":"BRIDG mapping path for CDE:58208","type":"BRIDG Mapping Path","description":"PerformedDiagnosis [1] > AssessedResultRelationship > PerformedObservation > PerformedDiagnosis.value [2] WHERE PerformedDiagnosis.value [1] = \"chronic lymphocytic leukemia(CLL)\" AND PerformedObservation.methodCode = \"Rai Staging\" AND AssessedResultRelationship.typeCode = \"classify\"","url":null,"context":"NHLBI"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"RAI Staging","url":null,"context":"ECOG-ACRIN"},{"name":"What was the Rai stage?","type":"Alternate Question Text","description":"What was the Rai stage?","url":null,"context":"NHLBI"},{"name":"What was the Rai stage?","type":"Application Standard Question Text","description":"What was the Rai stage?","url":null,"context":"NHLBI"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Rai Stage classification category","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B4AFFE76-9BCA-47C2-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-20","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-20","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"ISO 11179 Compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}